All News

2070 articles, sorted by publication time.

Biopharma · global

Hansoh’s HS-20093 Phase 3 Small Cell Lung Cancer Trial Meets Endpoint, Bringing a Survival Signal to the ADC Race

In small cell lung cancer, where treatment options are limited and relapse is rapid, a positive result using overall survival as the primary endpoint puts B7-H3-directed ADCs back at a clinical turning point; but full data have not yet been disclosed, and the result’s true weight will still depend on the magnitude of efficacy and safety details.